Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Levosimendan in Acute and Advanced Heart Failure : An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. / Altenberger, Johann; Gustafsson, Finn; Harjola, Veli-Pekka; Karason, Kristjan; Kindgen-Milles, Detlef; Kivikko, Matti; Malfatto, Gabriella; Papp, Zoltán; Parissis, John; Pollesello, Piero; Pölzl, Gerhard; Tschöpe, Carsten.

In: Journal of Cardiovascular Pharmacology, Vol. 71, No. 3, 2018, p. 129-136.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Altenberger, J, Gustafsson, F, Harjola, V-P, Karason, K, Kindgen-Milles, D, Kivikko, M, Malfatto, G, Papp, Z, Parissis, J, Pollesello, P, Pölzl, G & Tschöpe, C 2018, 'Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications', Journal of Cardiovascular Pharmacology, vol. 71, no. 3, pp. 129-136. https://doi.org/10.1097/FJC.0000000000000533

APA

Altenberger, J., Gustafsson, F., Harjola, V-P., Karason, K., Kindgen-Milles, D., Kivikko, M., Malfatto, G., Papp, Z., Parissis, J., Pollesello, P., Pölzl, G., & Tschöpe, C. (2018). Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of Cardiovascular Pharmacology, 71(3), 129-136. https://doi.org/10.1097/FJC.0000000000000533

Vancouver

Altenberger J, Gustafsson F, Harjola V-P, Karason K, Kindgen-Milles D, Kivikko M et al. Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. Journal of Cardiovascular Pharmacology. 2018;71(3):129-136. https://doi.org/10.1097/FJC.0000000000000533

Author

Altenberger, Johann ; Gustafsson, Finn ; Harjola, Veli-Pekka ; Karason, Kristjan ; Kindgen-Milles, Detlef ; Kivikko, Matti ; Malfatto, Gabriella ; Papp, Zoltán ; Parissis, John ; Pollesello, Piero ; Pölzl, Gerhard ; Tschöpe, Carsten. / Levosimendan in Acute and Advanced Heart Failure : An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. In: Journal of Cardiovascular Pharmacology. 2018 ; Vol. 71, No. 3. pp. 129-136.

Bibtex

@article{9ef19ec1b4d541f6a8bdae11c21f5534,
title = "Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications",
abstract = "The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.",
keywords = "Acute Disease, Cardiotonic Agents/adverse effects, Chronic Disease, Clinical Decision-Making, Congresses as Topic, Databases, Factual, Heart Failure/diagnosis, Humans, Myocardial Contraction/drug effects, Patient Selection, Recovery of Function, Risk Factors, Simendan/adverse effects, Treatment Outcome, Vasodilation/drug effects, Vasodilator Agents/adverse effects",
author = "Johann Altenberger and Finn Gustafsson and Veli-Pekka Harjola and Kristjan Karason and Detlef Kindgen-Milles and Matti Kivikko and Gabriella Malfatto and Zolt{\'a}n Papp and John Parissis and Piero Pollesello and Gerhard P{\"o}lzl and Carsten Tsch{\"o}pe",
year = "2018",
doi = "10.1097/FJC.0000000000000533",
language = "English",
volume = "71",
pages = "129--136",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams & Wilkins",
number = "3",

}

RIS

TY - JOUR

T1 - Levosimendan in Acute and Advanced Heart Failure

T2 - An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications

AU - Altenberger, Johann

AU - Gustafsson, Finn

AU - Harjola, Veli-Pekka

AU - Karason, Kristjan

AU - Kindgen-Milles, Detlef

AU - Kivikko, Matti

AU - Malfatto, Gabriella

AU - Papp, Zoltán

AU - Parissis, John

AU - Pollesello, Piero

AU - Pölzl, Gerhard

AU - Tschöpe, Carsten

PY - 2018

Y1 - 2018

N2 - The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.

AB - The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitizer and potassium channel-opener levosimendan has been proposed as a safer inodilator than traditional agents in some heart failure settings, such as advanced heart failure. At the 2017 annual congress of the Heart Failure Association of the European Society of Cardiology (Paris, April 30-May 2), a series of tutorials delivered by lecturers from 8 European countries examined how to use levosimendan safely and effectively in acute and advanced heart failure. The proceedings of those tutorials have been collated in this review to provide an expert perspective on the optimized use of levosimendan in those settings.

KW - Acute Disease

KW - Cardiotonic Agents/adverse effects

KW - Chronic Disease

KW - Clinical Decision-Making

KW - Congresses as Topic

KW - Databases, Factual

KW - Heart Failure/diagnosis

KW - Humans

KW - Myocardial Contraction/drug effects

KW - Patient Selection

KW - Recovery of Function

KW - Risk Factors

KW - Simendan/adverse effects

KW - Treatment Outcome

KW - Vasodilation/drug effects

KW - Vasodilator Agents/adverse effects

U2 - 10.1097/FJC.0000000000000533

DO - 10.1097/FJC.0000000000000533

M3 - Journal article

C2 - 28817484

VL - 71

SP - 129

EP - 136

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -

ID: 216202137